Literature DB >> 15385521

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.

Anja W Olsen1, Ann Williams, Limei M Okkels, Graham Hatch, Peter Andersen.   

Abstract

A fusion protein of antigen 85B (Ag85B) and ESAT-6 administered in cationic lipid vesicles conferred a highly significant level of protection against Mycobacterium tuberculosis in the guinea pig aerosol model of infection. The protection was manifested as delayed clinical illness and prolonged survival. Neither Ag85B nor ESAT-6 (independently or as a cocktail) induced significant protection in this model.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15385521      PMCID： PMC517547          DOI： 10.1128/IAI.72.10.6148-6150.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  15 in total

1.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Comparison in sensitized and unsensitized guinea-pigs of tuberculin PPDs RT 23 and PPD-M by skin tests and lymphocyte stimulation tests. Effect of immunization time.

Authors:  K Hasløv; M W Bentzon; S Møller
Journal:  J Biol Stand       Date:  1986-04

Review 3.  Protective effect of BCG in experimental tuberculosis.

Authors:  D W Smith
Journal:  Adv Tuberc Res       Date:  1985

Review 4.  Variation in protection by BCG: implications of and for heterologous immunity.

Authors:  P E Fine
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

5.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

Authors:  M A Horwitz; B W Lee; B J Dillon; G Harth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.

Authors:  G A Colditz; C S Berkey; F Mosteller; T F Brewer; M E Wilson; E Burdick; H V Fineberg
Journal:  Pediatrics       Date:  1995-07       Impact factor: 7.124

8.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis.

Authors:  H Boesen; B N Jensen; T Wilcke; P Andersen
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

10.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441
View more
  62 in total

1.  New TB vaccines: is there a requirement for CD8 T cells?

Authors:  W Henry Boom
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  ESAT-6 inhibits production of IFN-gamma by Mycobacterium tuberculosis-responsive human T cells.

Authors:  Xisheng Wang; Peter F Barnes; Karen M Dobos-Elder; James C Townsend; Yoon-tae Chung; Homayoun Shams; Stephen E Weis; Buka Samten
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

3.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

4.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

5.  Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Authors:  Teresa M Wozniak; Anthony A Ryan; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis.

Authors:  Xun Liu; Jinxiu Peng; Lina Hu; Yanping Luo; Hongxia Niu; Chunxiang Bai; Qian Wang; Fei Li; Hongjuan Yu; Bingxiang Wang; Huiyu Chen; Ming Guo; Bingdong Zhu
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 7.  Evasion and subversion of antigen presentation by Mycobacterium tuberculosis.

Authors:  A Baena; S A Porcelli
Journal:  Tissue Antigens       Date:  2009-06-25

8.  Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.

Authors:  Jiuling Wang; Yaqing Qie; Wei Liu; Honghai Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

9.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  Early secreted antigenic target of 6-kDa protein of Mycobacterium tuberculosis primes dendritic cells to stimulate Th17 and inhibit Th1 immune responses.

Authors:  Xisheng Wang; Peter F Barnes; Fangfang Huang; Ivana B Alvarez; Pierre F Neuenschwander; David R Sherman; Buka Samten
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.